Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.05 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enriched outside the brain (neutrophils) | 0.10 |
| chemistry Open Targets | compounds already reach it: mavrilimumab, sargramostim, cibinetide | 0.81 |
| trials ClinicalTrials.gov | 4 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 6 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 5119
Sealed predictions
- CSF2RB in dopamine neurons, braak-0.42 (p 0.266) → -0.28 (p 0.472)receipt 5126
Swarm cases
receipt 5126: CSF2RB in dopamine neurons, braak
- power
- full sample -0.32 (p 0.198, n 18), 95% CI -0.68 to +0.17. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.29 (p 0.239, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.58 (p 0.011, n 18). not the mix.
- skeptic
- leave-one-out range -0.44 to -0.23, sign flips 0; without severely affected donors -0.32 (p 0.198, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CSF2RB in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts